We are entering the age of biosimilars, and the market for these copycat biologics is rapidly expanding – in 2017 alone the EMA approved 16 biosimilars for seven different originator products. Five of those originators – AbbVie’s Humira (adalimumab), Genentech’s Herceptin (trastuzumab), Biogen/Genentech’s Rituxan (rituximab), and Eli Lilly’s Humalog (insulin lispro) and Forsteo (teriparatide) – previously had no biosimilars approved in Europe.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,